Trial: 201706011

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physicians Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL)


III (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Myeloid and Monocytic Leukemia; Myeloproliferative Disease

Learn more about this study at: